MyoKardia's Mavacamten 'Impressive' In Hypertrophic Cardiomyopathy
Launch Planning Underway For The Biotech's Lead Candidate
MyoKardia is building up its organization to prepare for commercialization of mavacamten, a potential first-in-class agent for obstructive hypertrophic cardiomyopathy.
You may also be interested in...
Biotech regains full rights to a pair of targeted therapies for heart diseases, but will bear full development costs. MyoKardia says the agreement with Sanofi ended due to differences over commercial rights, not concerns about trial data.
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.